Thuc Nguyen Dan Do
Overview
Explore the profile of Thuc Nguyen Dan Do including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
Antiviral Res
. 2024 Sep;
231:105994.
PMID: 39237005
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV and HCV. For the treatment of infections...
2.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
bioRxiv
. 2024 May;
PMID: 38798406
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven a key in the successful treatment of infections with HIV and HCV. For the treatment of...
3.
Khan M, Clijsters M, Choi S, Backaert W, Claerhout M, Couvreur F, et al.
Neuron
. 2022 Nov;
110(23):3919-3935.e6.
PMID: 36446381
Can SARS-CoV-2 hitchhike on the olfactory projection and take a direct and short route from the nose into the brain? We reasoned that the neurotropic or neuroinvasive capacity of the...
4.
Do T, Claes S, Schols D, Neyts J, Jochmans D
Viruses
. 2022 May;
14(5).
PMID: 35632693
The emergence of new SARS-CoV-2 variants and the replacement of preceding isolates have been observed through B.1.1.7, B.1.351, B.1.617.2, and B.1.1.529 lineages (corresponding to alpha, beta, delta, and omicron variants...
5.
Abdelnabi R, Foo C, Kaptein S, Zhang X, Do T, Langendries L, et al.
EBioMedicine
. 2021 Sep;
72:103595.
PMID: 34571361
Background: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients. Methods: We here report...
6.
Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen L, et al.
EBioMedicine
. 2021 Jun;
69:103454.
PMID: 34186486
No abstract available.
7.
Do T, Donckers K, Vangeel L, Chatterjee A, Gallay P, Bobardt M, et al.
Antiviral Res
. 2021 Jun;
192:105122.
PMID: 34186107
There are, besides remdesivir, no approved antivirals for the treatment of SARS-CoV-2 infections. To aid in the search for antivirals against this virus, we explored the use of human tracheal...
8.
Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen L, et al.
EBioMedicine
. 2021 Mar;
66:103288.
PMID: 33752127
Background: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for...
9.
Nguyen C, Do T, Bruggemann R, Ten Oever J, Kolwijck E, Adang E, et al.
Int J Antimicrob Agents
. 2019 Jul;
54(6):790-797.
PMID: 31284041
The increasing incidence of infections caused by extended-spectrum beta-lactamase (ESBL)/AmpC-producing bacteria leads to increasing use of carbapenems and risk of carbapenem resistance. Treatment success of carbapenem-sparing beta-lactams (CSBs) for ESBL...